STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #708 by analyst upside · 2026-06-27
JBIO
Jade Biosciences, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+120.5%
implied upside to consensus target
Current Price $22.0
Consensus Target $48.5
Bull Target $74.0
Bear Target $40.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
8
Hold
0
Sell
0
52-Week Low $6.67
52-Week High $28.0
YTD Return +55.4%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E -9.6x
EPS (TTM) $-2.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.67
52-Week High $28.0
Current Price $22.0
Bear Target $40.0
Bull Target $74.0
● Now $22.0 ● Target $48.5
TRADING DATA
Avg Volume 945K
YTD Return +55.4%
Analyst Count 8
Consensus Buy
Upside to Target +120.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Jade Biosciences, Inc. (JBIO) is currently trading at $22.0 with a Wall Street consensus price target of $48.5, implying potential upside of 120.5% over the next 12 months. 8 analysts currently cover JBIO, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $74.0, while the most cautious has a target of $40.0.

JBIO operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 55.4% year-to-date and is currently trading near the upper end of its 52-week range of $6.67 – $28.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JBIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS ● Initiated
Buy 2026-06-15 33% win rate (6 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-06-02 Building track record
BTIG — Reiterated
Buy → Buy 2026-06-01 38% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-01 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-05-27 38% win rate (8 calls)
Guggenheim — Reiterated
Buy → Buy 2026-05-11 62% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-11 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-27 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →